These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 4154597)

  • 21. Prevention of pertussis among adolescents by vaccination: taking action on what we know and acknowledging what we do not know.
    Wharton M
    Clin Infect Dis; 2004 Jul; 39(1):29-30. PubMed ID: 15206049
    [No Abstract]   [Full Text] [Related]  

  • 22. Time relationships between injection of antigen and adjuvant. II. Immunosuppression induced by Bordetella pertussis vaccine when given before secondary antigenic stimulation.
    Finger H; Bartoschek M; Emmerling P
    Pathol Microbiol (Basel); 1972; 38(2):93-102. PubMed ID: 4337644
    [No Abstract]   [Full Text] [Related]  

  • 23. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.
    Mielcarek N; Debrie AS; Mahieux S; Locht C
    Clin Vaccine Immunol; 2010 Mar; 17(3):317-24. PubMed ID: 20107007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoprophylaxis in pertussis.
    Deb M
    J Commun Dis; 1984 Mar; 16(1):54-60. PubMed ID: 12055788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis.
    Mielcarek N; Riveau G; Remoué F; Antoine R; Capron A; Locht C
    Nat Biotechnol; 1998 May; 16(5):454-7. PubMed ID: 9592394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis.
    Vandebriel RJ; Gremmer ER; Vermeulen JP; Hellwig SM; Dormans JA; Roholl PJ; Mooi FR
    Vaccine; 2007 Mar; 25(12):2346-60. PubMed ID: 17224216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acellular pertussis vaccines.
    Poltera AA
    N Engl J Med; 1996 Jun; 334(23):1547; author reply 1547-8. PubMed ID: 8618620
    [No Abstract]   [Full Text] [Related]  

  • 28. Poly(lactide-co-glycolide) microencapsulation of vaccine antigens.
    Jones DH; McBride BW; Farrar GH
    J Biotechnol; 1996 Jan; 44(1-3):29-36. PubMed ID: 8717383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models.
    Li R; Cheng C; Chong SZ; Lim AR; Goh YF; Locht C; Kemeny DM; Angeli V; Wong WS; Alonso S
    Allergy; 2012 Oct; 67(10):1250-8. PubMed ID: 22909095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of the route of immunization on the protection of mice infected intracerebrally with Bordetella pertussis.
    Standfast AF; Dolby JM
    J Hyg (Lond); 1972 Sep; 70(3):487-501. PubMed ID: 4341998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of surface antigens in the protective potency of Bordetella pertussis suspensions as measured by the intracerebral challenge technique in mice.
    Holt LB; Spasojevíc V
    J Med Microbiol; 1968 Aug; 1(1):119-26. PubMed ID: 4318938
    [No Abstract]   [Full Text] [Related]  

  • 32. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.
    Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C
    Vaccine; 2008 Oct; 26(45):5722-7. PubMed ID: 18762220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Indices of the strength of collective pertussis immunity].
    Ryzhenko IM; Verezub LG; Vil'vovskaia RI; Tigraniants VN; Dubova ON
    Vrach Delo; 1981 Jul; (7):111-4. PubMed ID: 6269302
    [No Abstract]   [Full Text] [Related]  

  • 34. Investigation of an aerosol challenge model as alternative to the intracerebral mouse protection test for potency assay of whole cell pertussis vaccines.
    Canthaboo C; Xing D; Douglas A; Corbel M
    Biologicals; 2000 Dec; 28(4):241-6. PubMed ID: 11237360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Patient with pertussis was incapable for work for seven weeks].
    Sternberg D
    MMW Fortschr Med; 2009 Oct; 151(44):49-50. PubMed ID: 19957478
    [No Abstract]   [Full Text] [Related]  

  • 36. Further contributions to an improved pertussis vaccine: II. New findings in the development of a pertussis vaccine.
    Robbel L; Hungerer KD; Aktories K
    Behring Inst Mitt; 1984 Nov; (76):110-2. PubMed ID: 6098261
    [No Abstract]   [Full Text] [Related]  

  • 37. [Present and future of oral pertussis vaccination].
    Falk W; Höfler KH; Rosanelli K; Kurz R
    Fortschr Med; 1981 Sep; 99(34):1363-6. PubMed ID: 6116657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamics of transplacental transmission of pertussis antibodies in premature and full-term infants.
    Nomura M; Kuno-Sakai H; Kimura M; Ichikawa I
    Tokai J Exp Clin Med; 2003 Apr; 28(1):21-6. PubMed ID: 12880300
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.
    Knuf M; Zepp F; Meyer C; Grzegowski E; Wolter J; Riffelmann M; Wirsing von König CH
    Vaccine; 2006 Mar; 24(12):2043-8. PubMed ID: 16356597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Oral pertussis vaccination].
    Rosanelli K; Falk W
    Padiatr Padol; 1985; 20(1):95-102. PubMed ID: 3975064
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.